BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9566820)

  • 1. Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon.
    Frangeul L; Cresta P; Perrin M; Duverlie G; Khorsi H; Musset L; Opolon P; Huraux JM; Lunel F
    J Hepatol; 1998 Apr; 28(4):538-43. PubMed ID: 9566820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
    Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
    Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis.
    Magrin S; Craxì A; Fabiano C; Fiorentino G; Marino L; Almasio P; Pinzello GB; Palazzo U; Vitale M; Maggio A
    J Med Virol; 1992 Nov; 38(3):200-6. PubMed ID: 1283753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
    Pawlotsky JM; Darthuy F; Rémiré J; Pellet C; Udin L; Stuyver L; Roudot-Thoraval F; Duvoux C; Douvin C; Mallat A
    J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study.
    Flichman D; Colombatto P; Randone A; Baldi M; Bellati G; Negro F; Oliveri F; Colucci G; Verme G; Bonino F; Brunetto MR
    Clin Diagn Virol; 1997 May; 8(1):63-70. PubMed ID: 9248659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay.
    Zanella A; Conte D; Prati D; Mozzi F; Capelli C; Zanuso F; Fraquelli M; Bosoni P; Vianello L; Pappalettera M
    Hepatology; 1995 Apr; 21(4):913-7. PubMed ID: 7535737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
    Shindo M; Arai K; Okuno T
    J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia.
    Polzien F; Schott P; Mihm S; Ramadori G; Hartmann H
    J Hepatol; 1997 Jul; 27(1):63-71. PubMed ID: 9252075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation between reactivity to the NS-4 region peptides of hepatitis C virus (HCV) and clinical features among patients infected with HCV genotype 1b.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Kinjo F; Saito A; Nakayoshi T; Yamashiro A
    Microbiol Immunol; 1998; 42(4):299-303. PubMed ID: 9623917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of sera indeterminate by Ortho-HCV RIBA-2 by using three confirmatory assays for anti-hepatitis C virus antibody.
    Dussaix E; Charnaux N; Laurent-Puig P; Chopineau S; Laurian Y; Buffet C
    J Clin Microbiol; 1994 Sep; 32(9):2071-5. PubMed ID: 7529247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha.
    Löhr HF; Elste C; Dienes HP; Michel G; Braun HB; Meyer zum Büschenfelde KH; Gerken G
    J Hepatol; 1996 Sep; 25(3):292-300. PubMed ID: 8895007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.
    Khorsi H; Castelain S; Wyseur A; Izopet J; Canva V; Rombout A; Capron D; Capron JP; Lunel F; Stuyver L; Duverlie G
    J Hepatol; 1997 Jul; 27(1):72-7. PubMed ID: 9252076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.
    Hino K; Sainokami S; Shimoda K; Iino S; Wang Y; Okamoto H; Miyakawa Y; Mayumi M
    J Med Virol; 1994 Mar; 42(3):299-305. PubMed ID: 7516422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.